Cancer drugs and the heart: importance and management.

Progress in the detection and treatment of cancer has led to an impressive reduction in both mortality and morbidity. Due to their mechanism of action, however, conventional chemotherapeutics and some of the newer anti-cancer signaling inhibitors carry a substantial risk of cardiovascular side effects that include cardiac dysfunction and heart failure, arterial hypertension, vasospastic and thromboembolic ischaemia, dysrhythmia, and QT prolongation. While some of these side effects are irreversible and cause progressive cardiovascular disease, others induce only temporary dysfunction with no apparent long-term sequelae for the patient. The challenge for the cardiovascular specialist is to balance the need for life-saving cancer treatment with the assessment of risk from cancer drug-associated cardiovascular side effects to prevent long-term damage. This review discusses concepts for timely diagnosis, intervention, and surveillance of cancer patients undergoing treatment, and provides approaches to clinical uncertainties.

[1]  H. Boezen,et al.  Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Jong-Hyeon Jeong,et al.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Feldman,et al.  High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Choueiri,et al.  Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Flinn,et al.  Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.

[6]  D. V. Von Hoff,et al.  A historical perspective of anthracycline cardiotoxicity. , 2011, Heart failure clinics.

[7]  M. Gail,et al.  Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Munir Pirmohamed,et al.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[9]  C. Marosi,et al.  Prediction of venous thromboembolism in cancer patients. , 2010, Blood.

[10]  R. Kao,et al.  Overexpression of Vascular Endothelial Growth Factor 165 (VEGF165) Protects Cardiomyocytes Against Doxorubicin-Induced Apoptosis , 2010, Journal of chemotherapy.

[11]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[12]  Michael S. Ewer,et al.  Cardiotoxicity of anticancer treatments: what the cardiologist needs to know , 2010, Nature Reviews Cardiology.

[13]  R. Coombes,et al.  Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  V. Cornelius,et al.  Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials , 2010, BMC Cancer.

[15]  M. Maitland,et al.  Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.

[16]  T. Choueiri,et al.  Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Shenhong Wu,et al.  Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. , 2010, American journal of hypertension.

[18]  N. Pavlakis,et al.  Cardiotoxicity with 5‐fluorouracil and capecitabine: more than just vasospastic angina , 2010, Internal medicine journal.

[19]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[20]  David O. Martin,et al.  Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy. , 2010, The American journal of cardiology.

[21]  D. Pfister,et al.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Veglia,et al.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.

[23]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[24]  R. Autorino,et al.  Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Helen X. Chen,et al.  Adverse effects of anticancer agents that target the VEGF pathway , 2009, Nature Reviews Clinical Oncology.

[26]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[27]  M. Piccart-Gebhart,et al.  Cardiac toxicity with anti-HER-2 therapies-what have we learned so far? , 2009, Targeted Oncology.

[28]  F. Goldwasser,et al.  Hypertension as a surrogate marker for the activity of anti-VEGF agents. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  K. Stergiopoulos,et al.  Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis , 2009, Acta oncologica.

[30]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[31]  Narine Sarvazyan,et al.  Anthracycline cardiotoxicity: from bench to bedside. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Glick,et al.  Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  E. Perez,et al.  Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. , 2008, Mayo Clinic proceedings.

[34]  A. Kudelka,et al.  Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. , 2008, The Lancet. Oncology.

[35]  H. Dickinson,et al.  Cardioprotective interventions for cancer patients receiving anthracyclines. , 2008, The Cochrane database of systematic reviews.

[36]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[37]  Gary H Lyman,et al.  American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Munden,et al.  Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. D. De Keulenaer,et al.  Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure , 2007, Circulation.

[40]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[41]  A. Liem,et al.  [Myocardial ischaemia as a result of treatment with capecitabine]. , 2007, Nederlands tijdschrift voor geneeskunde.

[42]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[43]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  H. Kantarjian,et al.  Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.

[45]  H. V. D. van der Vliet,et al.  [Myocardial ischaemia as a result of treatment with capecitabine]. , 2007, Nederlands tijdschrift voor geneeskunde.

[46]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[47]  J. Elaerts,et al.  Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[48]  H. Caron,et al.  Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. , 2006, The Cochrane database of systematic reviews.

[49]  V. Valero,et al.  Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Douglas L Mann,et al.  Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.

[51]  B. Hesse,et al.  Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction , 2004, European journal of heart failure.

[52]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[53]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[54]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[56]  B. Zaret,et al.  Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era , 2003, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[57]  B. Jensen,et al.  Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  G. Martinelli,et al.  Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  D. Sawyer,et al.  Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity , 2002, Circulation.

[60]  J. Hartikainen,et al.  Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction , 2002, Journal of internal medicine.

[61]  S. Soignet,et al.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  J. Schulz-Menger,et al.  Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. , 2001, American heart journal.

[63]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[64]  R. Nagai,et al.  Elevated B-type natriuretic peptide levels after anthracycline administration. , 1998, American heart journal.

[65]  S. Lipsitz,et al.  Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. , 1997, Circulation.

[66]  C. Carrasco,et al.  Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. , 1994, Ultrastructural pathology.

[67]  S. Liu,et al.  Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. , 1993, The American journal of physiology.

[68]  E. Cook,et al.  Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  D. Urbanová The role of endomyocardial biopsy in the diagnosis and treatment of heart disease. , 1989, Acta Universitatis Carolinae. Medica.

[70]  S. Saletan Mitoxantrone: an active, new antitumor agent with an improved therapeutic index. , 1987, Cancer treatment reviews.

[71]  L. Mancuso Prinzmetal's angina during 5-fluorouracil chemotherapy. , 1987, The American journal of medicine.

[72]  S. Wallace,et al.  A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.